David Felson

@david_felson

clinical researcher at Boston University who runs the BU Clinical Research Training Program and is a prominent researcher studying arthritis esp osteoarthritis.

Boston, MA Joined July 2015

14 Following 70 Followers 11 Posts

Latest posts 5

David Felson @david_felson Dec 21, 2021

Progression of Knee Osteoarthritis with use of Intra‐articular Corticosteroids vs. Hyaluronic Acid onlinelibrary.wiley.com/doi/abs/10.100…

acrjournals.onlinelibrary.wiley.com Progression of Knee Osteoarthritis With Use of Intraarticular Glucocorticoids Versus Hyaluronic Acid Objective To determine whether intraarticular glucocorticoid (GC) injections are associated with increased knee osteoarthritis (OA) progression compared to hyaluronic acid (HA) injections, which...

David Felson @david_felson Jul 14, 2020

Next one on ra biological to treat osteoarthritis: reasons for hope. July 22 at noon EST. Sign up!

Arthritis Foundation @ArthritisFdn Jul 7, 2020

We recently kicked off a new forum series with leading research experts across the globe. These forums discuss the future of OA research and improving patient outcomes. Learn more and watch the first in the series, “Does Strong Muscle Matter in OA?” bit.ly/3ebOag9

View quoted post on X

David Felson @david_felson May 17, 2020

Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis . Paper shows impressive efficacy of this new approach to treatment. ja.ma/2y81YcK

David Felson @david_felson Feb 11, 2020

Nature will include reviewer comments and author responses in its published papers (if reviewer agrees). Good move for science transparency!

David Felson @david_felson Jan 30, 2020

New meta-analysis of IL inhibitor trials shows not only increased infection risk but increased cancer risk too. Definitely concerning but need more data. jamanetwork.com/journals/jaman…

jamanetwork.com Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin... This systematic review and meta-analysis examines the risk for serious infections, opportunistic infections, and cancers in individuals receiving interleukin inhibitor therapies for rheumatologic...